When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Did you know that 2 to 5% of women of reproductive age are affected by a more severe form of premenstrual syndrome (PMS) known as premenstrual dysphoric disorder…
A team of engineers are hoping the 12-sided cage they developed will one day help fight cancer. Made from self-assembling silica, the nanocage is only 11 nanometers across—for…
The gut microbiome is widely viewed as an exciting new treasure trove of medical insight. But the skin microbiome holds plenty of its own potential, including for patients…
Genetic testing for Parkinson’s risks can be useful to people with and without the disease. It can also help advance research into the complex condition. Although the testing…
